Mathurin Fumery

39PUBLICATIONS
84CO-AUTHORS
Biologically active moleculesCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Preventative health careInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Jul 16, 2026
Letter: Upadacitinib in Perianal Crohn's Disease: Does Clinical Closure Reflect True Remission? Authors' Reply.

|Mar 25, 2026
Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID.

Louis Calméjane, Catherine Reenaers, Claire Gay

|Mar 06, 2026
Subcutaneous infliximab in inflammatory bowel disease: bridging the gap between theory and practice.

Lucine Vuitton, Mathurin Fumery, Lucile Foulley

|Dec 02, 2025
Intestinal Ultrasound Transmural Healing Was Associated With Improved Long-Term Outcomes Among Patients With Endoscopic Remission: Results of a Prospective Study.

Clara Yzet, Amélie Plancke, Franck Brazier

|Aug 28, 2025
Subcutaneous Infliximab for Perianal Crohn's Disease: The BioLap-Rem Multicenter Study From the GETAID.

Marie André, Julien Kirchgesner, David Laharie

|Aug 25, 2025
Comparing standard versus intensified pneumococcal vaccination regimens in patients with inflammatory bowel disease on biologics: a prospective, multicenter, randomized, open-label study.

Xavier Roblin, Sophie Vieujean, Stéphane Nancey

Pageof 7

Frequent Collaborators

10 joint publications

Laurent Peyrin-Biroulet

9 joint publications

Anthony Buisson

9 joint publications

David Laharie

8 joint publications

Guillaume Bouguen